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Cutis laxa is a heterogeneous group of disorders characterized by loose, lax, and inelastic skin.  Other 
complications include lung, cardiovascular, musculoskeletal, gastrointestinal, and genitourinary 
disease.  Cutis laxa (CL) can be congenital or acquired, with the congenital forms resulting from 
mutations in numerous genes.  Chronic obstructive pulmonary disease (COPD) is a major contributor 
to morbidity and mortality in CL, making it a subject of public health importance.  This purpose of 
this analysis is to determine quantitative differences between CL onset, congenital and acquired, and 
CL diagnosis, CL versus CL carrier in regard to pulmonary function and disability that results from 
lung dysfunction.  An odds ratio determined that the cutis population has an increased risk for COPD 
and t-test analysis determined that COPD severity was the same between congenital and acquired 
subjects, but significantly different between CL and CL carriers.  Multiple people with a previous 
asthma diagnosis were determined to actually have COPD.  Additionally, the SGRQ total score was 
found to be highly correlated with FEV1/FVC and CT visual emphysema score.  Further studies are 
warranted to more clearly determine genotype-phenotype correlations and assess longitudinal 
changes. 
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1.0  INTRODUCTION 
Cutis laxa (CL) is an inherited or acquired connective tissue disease characterized by loose, lax, 
and inelastic skin.  The inherited forms of CL are genetically heterogeneous, with significant 
variable expressivity seen in each genetic subtype.  To date, mutations in the following genes 
have been shown to cause CL: fibulin-4 (FBLN4) or EGF containing fibulin-like extracellular 
matrix protein 2 (EFEMP2) gene, fibulin-5 (FBLN5), latent transforming growth factor beta 
binding protein 4 (LTBP4), ATPase, H+ transporting, lysosomal V0 subunit a2 (ATP6V0A2), 
pyrroline-5-carboxylate reductase 1 (PYCR1), elastin (ELN), golgin, RAB6-interacting 
(GORAB), and Ras and Rab interactor 2 (RIN2) (Berk et al 2012, Morava et al 2009).  All of 
these genes have a role in the extracellular matrix, with their disruption causing a highly variable 
phenotype.   
The skin findings in cutis laxa are primarily loose, lax, redundant, and inelastic skin, 
giving an aged appearance to the individual.  Pulmonary disease is highly variable, with the most 
common findings including tachypnea, recurring respiratory infections, and chronic obstructive 
pulmonary disease, specifically emphysema.  Cardiovascular disease includes aortic dilation and 
aneurysm, arterial tortuosity, and stenosis.  Other systems possibly affected include the 
musculoskeletal, and the gastrointestinal and genitourinary systems, with the most common 
features including hernias and joint laxity, and diverticula, respectively.  Some individuals with 
cutis laxa also experience growth and/or developmental delay. 
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While the various forms of CL have been described in detail, there has not been a study 
to examine differences in lung function between congenital and acquired forms of CL.  While 
COPD has been described as a feature in many subtypes of CL, no study has looked to formally 
assess what the increased risk for COPD is in CL.  Additionally, the disability and morbidity 
associated with CL can be inferred for those familiar with the phenotype and by anecdotal 
communications, but has never been assessed quantitatively.  This study will aim to address all 
of these gaps in the literature.  
1.1 OBJECTIVE 
The objective of this study is to better define the pulmonary phenotype and disability from lung 
dysfunction in cutis laxa.  The pulmonary phenotype was assessed by cutis laxa onset 
classification as well as by genotype through pulmonary function tests (PFTs), chest computed 
tomography (CT) and by respiratory questionnaire analysis. 
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2.0  BACKGROUND 
2.1 CUTIS LAXA AND THE EXTRACELLULAR MATRIX 
Elastic fibers are the main component of the extracellular matrix, providing structure and 
elasticity to the skin. In the skin, elastic fibers are composed of a core of elastin that is 
surrounded by microfibrils, which contain fibrillins and microfibril-associated glycoproteins 
(Lewis et al 2004).  In cutis laxa, mutations in various genes and/or environmental effects lead 
either to improper elastin and microfibril assembly or to the destruction of existing elastic fibers, 
which leads to compromised skin structure (Figure 1) and elasticity (Hu et al 2010). 
 
  
 
 
 
 
 
 
Figure 1. left, electron microscopy (EM) of an unaffected individual, showing normal elastin and 
microfibril ultrastructure, 1100x direct magnification; right, EM of an individual with CL, 
showing abnormal elastic fiber ultrastructure characterized by a moth-eaten appearance, 6800x 
direct magnification. 
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While the skin features are the hallmark of cutis laxa, connective tissue is found 
throughout the body, including the cardiovascular system, pulmonary system, gastrointestinal 
system, and genitourinary system (Badylak et al 2008). Abnormal biogenesis or damage to 
elastin and the extracellular matrix leads to manifestations in these body systems, although the 
specific expression and involvement is subtype-dependent, with different patient subsets 
showing different manifestations (Lewis et al 2004). 
2.2 CHRONIC PULMONARY DISEASE 
2.2.1 Chronic Obstructive Pulmonary Disease (COPD) 
According to the GOLD criteria, an international NHLBI and WHO Initiative for COPD 
diagnoses and management summary, chronic obstructive pulmonary disease (COPD) is an 
airflow limitation that is not fully reversible (Pauwels et al 2001).  COPD is also defined by 
Pauwels et al (2001) as a spirometry FEV1/FVC post-bronchodilation percent predicted value 
less than or equal to 70%.  COPD is a multifactorial disease, influenced by many genetic factors, 
for example by alpha-1 antitrypsin (AAT) deficiency, and environmental factors (ALA 2008).  
The most common environmental risk factor is smoking, with other environmental factors 
including air pollution, second-hand smoke, and recurrent respiratory infections (ALA 2008).  
The World Health Organization (WHO) (2008) estimates that 64 million people worldwide had 
COPD in 2004, with COPD contributing 5% of all deaths worldwide in 2005.  COPD has 
become a disease of international public health importance, and will only continue to become 
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more prevalent. In 2002 COPD was the fifth leading cause of death in the world, and is expected 
to become the third leading cause of death by the year 2030 (WHO 2008). 
While COPD can be easily diagnosed and there are established treatments, many people 
do not realize they have COPD when it is in the early stages.  Symptoms of COPD include 
recurrent respiratory infections, fatigue, dyspnea, and exercise intolerance (ALA 2008).  COPD 
is most accurately diagnosed by performing spirometry, as part of a pulmonary function test 
(PFT) (Pauwels et al 2001).  Spirometry is used to determine FEV1/FVC (where FEV1 is the 
forced expiratory flow in 1 second and FVC is the forced vital capacity), which, when less than 
0.70, is diagnostic of COPD, with FEV1 indicates the severity of the obstruction, as detailed in 
Table 1 (Mohamed Hoesein et al 2011, Pauwels et al 2001). 
Table 1. FEV1 determines severity of COPD (Pauwels et al 2001) 
 
Stage of COPD FEV1 % predicted 
Mild FEV1 ≥ 80% predicted 
Moderate 30% ≤ FEV1 < 80% predicted 
Severe FEV1 < 30% predicted 
 
The NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines, originally developed by Pauwels et al (2001) detailed management guidelines for 
COPD with four main components of management: Assess and Monitor Disease Diagnosis, 
Reduce Risk Factors, Manage Stable COPD, and Manage Exacerbations.  Assessing and 
monitoring disease diagnosis is done through spirometry, monitoring symptoms, and reviewing 
risk factors and medical history.  Successful ways to alter these risk factors include reducing or 
eliminating smoking and smoke exposure, exposure to air pollution, and any occupational 
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exposures.  Managing stable COPD is done through health education, inhaled 
glucocorticosteroids and bronchodilators, both when indicated, oxygen treatment, and an 
exercise training program to improve exercise intolerance, dyspnea, and fatigue.  Acute 
exacerbations, most commonly respiratory infections, are treated with antibiotics, 
glucocorticosteroids, and/or bronchodilators, depending on the nature of the infection. (Pauwels 
et al 2001) 
The SGRQ, which was the respiratory questionnaire used for disability and lung 
dysfunction analysis in this study, is one of the most commonly used quality of life questionnaire 
in COPD studies, provides physical health-related quality of life scores caused by COPD lung 
dysfunction (Ferrer et al 2002).  The SGRQ is a validated questionnaire with an available scoring 
manual (Ferrer et al 2002).  The SGRQ assesses what pulmonary symptoms someone has, what 
activities are affected by one’s lung disease, and the level of impact in day-to-day life from lung 
dysfunction (Ferrer et al 2002).  The scores that are determined from the SGRQ questions are 
total score, symptom score, activity score, and impact score (Ferrer et al 2002).  This is the first 
use of the SGRQ questionnaire in the cutis laxa population. 
2.2.1.1 Emphysema 
Emphysema is one of the two main pathological hallmarks of COPD characterized by the 
destruction of the alveoli, leading to a reduction of the internal surface area of the lung available 
for gas exchange, an enlargement of the air spaces and hyperinflation of the lung (ALA 2010).  
Emphysema also leads to the collapse of bronchioles and bronchi during exhalation, leading to 
air trapping in the lungs (Pauwels et al 2001).  While treatment may ease symptoms, current 
medications cannot reverse or stop lung damage from occurring (Pauwels et al 2001). Thus, even 
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after elimination of environmental and behavioral risk factors, such as smoking, emphysema 
(and COPD) tends to worsen with time (Pauwels et al 2001). 
2.2.1.2 Chronic Bronchitis 
Chronic bronchitis is the second main pathological manifestation of COPD characterized 
by inflammation of the bronchi, with the most common symptom being chronic cough that 
produces mucus or sputum (Pauwels et al 2001).  Bronchodilators are the most commonly used 
treatment to counteract the inflammation and to relieve COPD symptoms (Pauwels et al 2001). 
2.2.2 Other Pulmonary Disease 
Other pulmonary diseases noted in cutis laxa patients are pneumonia, upper respiratory 
infections, and asthma.  Viral and bacterial infections are known exacerbations of COPD that can 
lead to significant changes in quality of life (Wedzicha et al 2003).  Asthma, which is defined as 
obstructive lung disease that is intermittent and completely reversible with bronchodilation, 
differs from COPD, which is considered progressive and irreversible (Zeki et al 2011).   
2.3 TYPES OF CUTIS LAXA 
Cutis laxa is a group of heterogeneous disorders with ten currently described causative genes for 
CL or CL-like disorders.  A summary of all CL subtypes is described in Table 2. 
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Table 2. Summary of Cutis Laxa Subtypes 
 
CL Type Inheritance Main Features 
ARCL1A AR (FBLN4) Cutis laxa, arterial tortuosity, aortic aneurysm, 
emphysema, hernias, joint laxity 
ARCL1B AR (FBLN5) Cutis laxa, supravalvular aortic stenosis, emphysema, 
hernias 
ARCL1C 
(URDS) 
AR (LTBP4) Cutis laxa, emphysema, diverticula, intestinal 
dilation/tortuosity, hernias, joint laxity 
ARCL2A AR (ATP6V0A2) Cutis laxa, delayed closure of the fontanelles, joint laxity, 
developmental delay, seizures 
ARCL2B AR (PYCR1) Cutis laxa on the hands and feet, triangular shaped face, 
joint laxity, developmental and growth delay 
ARCL3 AR (ATP6V0A2, 
PYCR1, ALDH18A1) 
Cutis laxa, joint laxity, cornea opacities, cataracts, 
progeroid-like features 
ADCL AD (ELN) Cutis laxa, aortic dilation and aneurysm, emphysema, 
hernias 
OHS XL (ATP7A) Cutis laxa, occipital horns, hernias, bladder diverticula 
GO AR (GORAB) Cutis laxa on dorsum of hands and feet, joint 
hyperextensibility, decreased bone density, dwarfism 
MACS AR (RIN2) Macrocephaly, Alopecia, cutis laxa, scoliosis 
Acquired Likely multifactorial Cutis laxa, emphysema, aortic dilation, hernias 
2.3.1 Autosomal Recessive Cutis Laxa Type 1A (ARCL1A) 
Autosomal recessive cutis laxa type 1A (ARCL1A) is caused by mutations in the fibulin-4 
(FBLN4) or EGF containing fibulin-like extracellular matrix protein 2 (EFEMP2) gene, as 
originally described by Hucthagowder et al (2006).  The main features of FBLN4-related cutis 
laxa include loose, lax, and redundant skin, arterial tortuosity, aortic aneurysm, developmental 
emphysema, hernias, and musculoskeletal findings that include joint laxity, multiple fractures, 
and pectus excavatum (Hucthagowder et al 2006).  Additional publications revealed some 
FBLN4 mutations occurring with arterial tortuosity and aneurysm, but without the characteristic 
skin findings or emphysema (Renard et al 2010).  The presence of significant heterogeneity 
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among individuals with ARCL1A was also noted by Dasouki et al (2007) and Hoyer et al (2009), 
with the children in both of these reports passing away from complications at less than one 
month of age. 
2.3.2 Autosomal Recessive Cutis Laxa Type 1B (ARCL1B) 
Autosomal Recessive Cutis Laxa type 1B (ARCL1B) is known to be caused by mutations in 
fibulin-5 (FBLN5), a gene known to be part of the elastic fiber network, which is found in many 
different tissues, including the aorta, lungs, and skin (Loeys et al 2002).  Fibulin-5 protein is 
necessary for proper assembly of microfibrils and elastin, which are interrupted by fibulin-5 
mutations, ultimately resulting in improper microfibril and elastin assembly, which in turn lead 
to loose, redundant skin, as well as emphysema and other complications in individuals with 
ARCL1B (Hu et al 2006).  While the most common features of ARCL1B are skin laxity, 
supravalvular aortic stenosis (SVAS), emphysema, and hernias, the phenotype is heterogenous, 
with reports of variable expressivity among members of the same family (Loeys et al 2002 and 
Berk et al 2012).  In addition to phenotypic heterogeneity, genetic heterogeneity is common in 
FBLN5 related cutis laxa, with missense mutations and duplications as well as recessive and 
dominant inheritance being reported (Loeys et al 2002 and Markova et al 2003). 
2.3.3 Urban-Rifkin-Davis Syndrome (URDS) or Autosomal Recessive Cutis Laxa Type 
1C (ARCL1C) 
In 2009, Urban et al found that mutations in the gene for the latent transforming growth factor-β 
binding protein 4 (LTBP4) caused ARCL1C, primarily characterized by cutis laxa, emphysema, 
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gastrointestinal, genitourinary, and musculoskeletal findings.  Mutations in LTBP4 led to 
increased transforming growth factor-β (TGF-β) activity, which negatively affected the elastic 
fiber organization and ultrastructure (Urban et al 2009).   
Improper elastic fiber formation due to mutations in LTBP4 creates a wide range of 
complications.  Craniofacial features noted in the first group of identified LTBP4-related cutis 
laxa included hypertelorism, micrognathia, and a long philtrum.  Pulmonary findings were seen 
in all four of the original patients, with findings ranging from pneumonia, chronic respiratory 
infections, tachypnea, and generalized respiratory distress, which was severe enough in one 
patient to require a tracheotomy.  Gastrointestinal and genitourinary findings included rectal and 
cervical prolapse, inguinal, umbilical, diaphragmatic, and pelvic floor hernias, dilation and/or 
tortuosity of the gastrointestinal tract, tortuous blood vessels, diverticula in the stomach, 
intestines, and bladder, as well as pyloric stenosis and hydronephrosis. (Urban et al 2009) 
2.3.4 Autosomal Recessive Cutis Laxa Type 2A (ARCL2A) 
Autosomal Recessive Cutis Laxa Type 2A (ARCL2A) is caused by mutations in ATP6V0A2, the 
gene encoding the a2 subunit of the vacuolar H+ -ATPase, which is involved in pH regulation 
(Kornak et al 2008).  ARCL2A is part of a larger class of disorders known as the congenital 
disorders of glycosylation (CDG), which is characterized by disturbed glycosylation in the Golgi 
apparatus  
(Morava et al 2009).  There is ubiquitous expression of ATP6V0A2, leading many possible 
tissues being affected (Guillard et al 2009).  Hucthagowder et al (2009) demonstrated that the 
mechanism for ATP6V0A2-related CL is through loss of function mutations, which leads to 
reduced mRNA levels in fibroblasts. Loss of ATP6V0A2 function in turn caused defective 
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secretion of the elastin precursor, tropoelastin (Hucthagowder et al 2009).  Of note, Wrinkly Skin 
Syndrome (WSS) is an allelic syndrome that is characterized by wrinkled skin, microcephaly, 
intellectual disability, and musculoskeletal complications (Morava et al 2009, Kornak et al 
2008). 
ARCL2A is characterized by congenital cutis laxa, delayed closure of fontanelles, 
congenital eye anomalies, growth, and developmental delay, and characteristic facies that include 
downslanting palpebral fissures, broad flat nasal bridge, and anteverted nostrils, narrow face 
(Noordam et al 2009). Other features include low bone density, including osteopenia and 
osteoporosis, lax joints, hypotonia, cobblestone like brain dysgenesis, and hernias 
(Hucthagowder et al 2009, Morava et al 2009).  While it was previously believed that there were 
no pulmonary or cardiovascular findings that are more commonly found in other types of CL, 
our data has shown abnormal pulmonary function test (PFT) results in one ATP6V0A2 compound 
heterozygote, as well as physician reported aortic dilation in a young ATP6V0A2 homozygote (Z. 
Urban unpublished data). 
2.3.5 Autosomal Recessive Cutis Laxa Type 2B (ARCL2B) 
Autosomal recessive cutis laxa type 2B (ARCL2B) is caused by mutations in PYCR1, a gene 
expressed highly in the bones and skin (Mohamed et al 2011).  Unlike ATP6V0A2-related CL, 
PYCR1-related CL is not a CDG (Berk et al 2012). Nevertheless, the clinical features of the two 
disorders are highly similar, with characteristic features of ARCL2B including cutis laxa on the 
dorsum of hands and feet, low bone density, joint laxity, intellectual disability, speech delay, 
dysmorphic features, which include a triangular shaped face with large ears, large fontanelles, 
microcephaly, adducted thumbs, contractures, and intrauterine growth retardation (IUGR) 
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(Mohamed et al 2011, Kouwenberg et al 2011).  While there are many overlapping features with 
other disorders, including ARCL2A, gerodermia osteodysplastica (GO), ARCL2B is a distinct 
subtype of CL. 
2.3.6 Autosomal Recessive Cutis Laxa Type 3 (ARCL3) or De Barsy Syndrome 
Autosomal recessive cutis laxa type 3 (ARCL3) or De Barsy Syndrome is characterized 
by cutis laxa, progeria-like appearance, dysmorphic features, significant ophthalmologic 
abnormalities, neurologic, and musculoskeletal anomalies (Kivuva et al 2008 and Morava et al 
2009). Ophthalmologic abnormalities in ARCL3 include corneal opacities, cataracts, strabismus, 
and myopia (Kivuva et al 2008).  While some eye abnormalities have been reported in other 
subtypes of ARCL, ARCL3 has the most severe findings (Berk et al 2012).  ARCL3 overlaps 
both clinically and genetically with ARCL2. Mutations in patients diagnosed with ARCL3 have 
been found in ATP6V0A2 (Kornak et al. 2008), in PYCR1 (Reversade et al. 2009) and in the 
gene for another mitochondrial enzyme in the proline biosynthetic pathway, ALDH18A1 
(Bicknell et al. 2008, Skidmore et al. 2011). 
2.3.7 Autosomal Dominant Cutis Laxa (ADCL) 
Autosomal dominant cutis laxa (ADCL) is caused primarily by mutations in elastin (ELN), with 
the most common molecular findings being frameshift mutations in exons 28-34 (Callewaert et 
al 2011).  There has also been a reported case of a heterozygous FBLN5 mutation causing ADCL 
(Markova et al. 2003). ELN mutations leading to CL show increased TGF-β activity, similar to 
the findings in LTBP4-related CL (Hu et al 2010, Callewaert et al 2011). 
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ADCL is characterized by the typical facial appearance with loose, lax skin, large ears, 
emphysema, aortic aneurysm, and hernias (Urban et al 2005, Callewaert et al 2011, and Szabo et 
al 2006).  While it was once thought that there were few internal organ complications, it is now 
apparent that aortic aneurysm and emphysema are consistent with ADCL. Callewaert et al (2011) 
described four of six ADCL cases cause by mutations in ELN had some type of aortic dilation, 
one of six had chronic obstructive pulmonary disease (COPD), and an additional two of six 
individuals had more minor pulmonary findings, which included recurrent upper airway 
infections and dyspnea.  Szabo et al (2006) described two families with ELN-related ADCL, with 
some affected family members having aortic dilation, but detailed lung function testing was not 
reported.   
2.3.8 Occipital Horn Syndrome (OHS) 
Occipital Horn Syndrome (OHS) or X-linked recessive CL (XLCL) is a type of cutis laxa allelic 
to Menkes disease, with OHS being the mildest form of the Menkes spectrum of disease (Tumer 
et al 2010).  OHS is caused by mutations in ATP7A, a copper-transporting adenosine 
triphosphatase (Tumer et al 2010).  The most distinguishable feature in OHS is occipital horns, 
which become more prominent with age (Tumer et al 2010).  There is also skin laxity, bladder 
diverticula, hernias, and generalized connective tissue problems (Tumer et al 2010).  While there 
are neurologic deficits in Menkes disease, OHS does not typically have these features (Berk et al 
2012).  Additionally, low serum copper and ceruloplasmin levels may be present in OHS, 
helping to distinguish OHS from the other forms of CL (Tumer et al 2010, Kaler et al 1998, 
Borm et al 2004).  
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2.3.9 Gerodermia Osteodysplastica (GO) 
Gerodermia Osteodysplastica (GO) is a rare connective tissue disorder caused by mutations in 
GORAB, previously known as SCYL1BP1 (Yildirim et al 2011).  GO has many overlapping 
features of CL, especially with ARCL2, which include skin wrinkling on the dorsum of the 
hands and feet, hyperextensible joints, decreased bone density with frequent fractures, dwarfism 
(Kouwenberg et al 2011, Yildirim et al 2011).  Differentiating GO from ARCL2B, is a lack of 
intellectual and speech delay, frequently seen in those with PYCR1 mutations (Kouwenberg et al 
2011).  Unlike ARCL and ADCL, GO does not have significant cardiovascular or pulmonary 
involvement (Noordam et al 2009). 
2.3.10 Macrocephaly, Alopecia, Cutis Laxa, and Scoliosis (MACS) Syndrome 
Macrocephaly-alopecia-cutis laxa-scoliosis (MACS) syndrome, caused by recessive mutations in 
RIN2, is characterized by macrocephaly, sparse hair, cutis laxa, scoliosis, facial dysmorphism, 
joint hypermobility, and dental anomalies (Basel-Vanagaite et al 2009).  There can also be 
gingival hyperplasia and hernias (Berk et al 2012).  Mutations in RIN2 lead to low amounts of 
dermal microfibrils and abnormal endocytic trafficking, which ultimately leads to the disease 
phenotype (Basel-Vanagaite et al 2009). 
2.3.11 Late-Onset/Acquired Cutis Laxa 
Late-onset or acquired cutis laxa (ACL) is considered in individuals who have developed cutis 
laxa signs and symptoms after childhood.  While the exact mechanism of acquired cutis laxa is 
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not known, it is believed to be multifactorial in nature. It is known that a variety of 
environmental factors can trigger the development of acquired CL, including: inflammatory 
disease, multiple myeloma and lymphoma, autoimmune diseases, and allergies to certain 
medications (Berk et al 2012).  While it has been suggested that there is a genetic component to 
acquired CL (Hu et al. 2006), the nature of this genetic predisposition is not yet clear.   
The phenotype of ACL is highly variable, with symptoms usually progressing with time.  
Skin findings are similar to the inherited forms of CL, with systemic findings including COPD, 
aortic dilations, gastrointestinal and genitourinary diverticula and prolapse, and hernias (Berk et 
al 2012, Kim et al 2011, New et al 2011, Mehta et al 2011). 
2.4 CLINICAL FEATURES 
2.4.1 Skin Findings in Cutis Laxa 
Loose, lax, and redundant skin is the hallmark of cutis laxa, but the severity of the skin findings 
and whether the skin findings are generalized or localized, varies greatly among the different 
subtypes of CL.  ADCL, ARCL1A, ARCL1B, ARCL1C, ARCL3, OHS, and MACS usually 
have generalized skin findings, although the severity can be highly variable (Berk et al 2012 and 
Morava et al 2009). ARCL2B and GO are differentiated by skin findings being mostly localized 
to the dorsum of the hands and feet (Yildirim et al 2011 and Mohamed et al 2011).  
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2.4.2 Pulmonary Disease in Cutis Laxa 
The most common pulmonary manifestation in CL is COPD, which can be seen in ADCL, 
ARCL1A, ARCL1B, ARCL1C, ARCL2A, and acquired CL (Hucthagowder et al 2006, Loeys et 
al 2002, Urban et al 2009, Z. Urban unpublished data, Berk et al 2012, Urban et al 2005, 
Callewaert et al 2011).  COPD can be diagnosed by spirometry, which is performed as part of a 
PFT (Pauwels et al 2001).  While COPD cannot be cured or even partially reversed, it is possible 
to treat the symptoms in order to improve quality of life and day-to-day activities (Pauwels et al 
2001).   
2.4.3 Cardiovascular Disease in Cutis Laxa 
The most common cardiovascular complication in CL is aortic dilation and aneurysm, with other 
complications including arterial tortuosity, supravalvular aortic stenosis (SVAS), pulmonary 
artery stenosis, and regurgitation (Berk et al 2012).  Aortic dilation is most commonly found in 
ARCL1A, ADCL, and acquired CL (Hucthagowder et al 2006, Urban et al 2005, Callewaert et al 
2011). Arterial tortuosity is most commonly seen in ARCL1A and can affect any of the arteries, 
including the aorta (Hucthagowder et al 2006).  SVAS, which is the narrowing of the ascending 
aorta near the aortic valve, is most commonly seen in ARCL1B and ADCL (Urban et al 2005, 
Callewaert et al 2011, Loeys et al 2002).  Pulmonary artery stenosis is most common in 
ARCL1C and can lead to shortness of breath, fatigue, and a fast heart rate as oxygenation is poor 
when the pulmonary artery is narrowed (Urban et al 2009).   
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2.4.4 Musculoskeletal Disease in Cutis Laxa 
Musculoskeletal disease is a common feature of CL, with the most common musculoskeletal 
features including joint laxity or hypermobility, bone fractures, and decreased bone density 
found in ARCL1A, ARCL1C, ARCL2A, ARCL2B, OHS, and MACS (Urban et al 2009, 
Hucthagowder et al 2009, Morava et al 2009, Mohamed et al 2011, Kouwenberg et al 2011, and 
Yildirim et al 2011). An increased rate of bone fracture is seen in ARCL1A and GO, with 
decreased bone density most common in ARCL2A and ARCL2B (Hucthagowder et al 2006, 
Kouwenberg et al 2011, and Yildirim et al 2011).  Less common musculoskeletal findings 
include pectus excavatum in ARCL1A and scoliosis in MACS (Hucthagowder et al 2006, Basel-
Vanagaite et al 2009). 
2.4.5 Diverticula and Hernias in Cutis Laxa 
Hernias and diverticula in cutis laxa are highly variable in location and severity.  Numerous 
types of hernias can be seen in all subtypes of ARCL1, ARCL2A, ADCL, OHS, and acquired CL 
(Berk et al 2012, Urban et al 2009, Hucthagowder et al 2006, Loeys et al 2002).  Types of 
hernias seen include inguinal, hiatal, umbilical, and diaphragmatic.  Diverticula can be seen in 
ARCL1C and OHS, with most diverticula occurring in the bladder and intestines, but has been 
reported throughout the gastrointestinal tract as well (Urban et al 2009 and Tumer et al 2010). 
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3.0  HYPOTHESIS AND SPECIFIC AIMS 
Genetic, clinical and pathological information available to date support the notion that cutis laxa 
is a key feature of a group of diseases caused by elastic fiber dysfunction (Berk et al. 2012). 
Whereas congenital cutis laxa is mostly inherited and characterized by an abnormality of elastic 
fiber formation, in individuals with acquired or late-onset cutis laxa the elastic fibers appear to be 
formed properly but are destroyed by inflammatory or immune-mediated processes. Thus, 
comparative studies of congenital vs. acquired cutis laxa allow for the dissection of the 
importance of elastic fibers in the development vs. the maintenance of organ function. Based on 
current understanding of the role of elastic fibers in lung development and physiology (Shifren et 
al 2006) and previous case reports on cutis laxa, we hypothesized that both congenital and 
acquired CL patients have increased risk of developing COPD. Furthermore, we hypothesized 
that COPD in patients with cutis laxa has a significant impact on their quality of life. To test 
these hypotheses, we had the following specific aims: 
3.1.1 Specific Aim 1 
Determine the nature of the pulmonary disease and clinical differences in a variety of patients 
with congenital or acquired cutis laxa through PFT analysis. 
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3.1.2 Specific Aim 2 
Assess the significance of pulmonary dysfunction and disability in the cutis laxa population in 
attendance of the University of Pittsburgh clinics. 
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4.0  METHODS 
The data collected for this study was obtained under IRB approval at University of Pittsburgh, 
Washington University at St. Louis, and University of Hawaii, with IRB approval letters 
included in Appendix A.  This study is currently funded through NIH by NHLBI. 
4.1 CLINIC PROTOCOL 
4.1.1 Recruitment 
Research subject recruitment is primarily by self- or physician-referral. Other ways subjects are 
recruited include through the online patient support group, through a genetic counselor, or 
through family members already enrolled in the study. 
4.1.2 Screening 
Screening was performed on each individual to determine eligibility for participation, with 
eligibility consisting of a confirmed or suspected diagnosis in the individual or one of his/her 
first-degree relatives.  All individuals were asked if he/she or his/her affected first-degree relative 
had (1) loose, lax skin, (2) skin in redundant folds, (3) inelastic or doughy skin, (4) premature 
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aging of the skin, (5) excessive premature wrinkling, or (6) another family member affected with 
cutis laxa.  Any individual answering “yes” to at least three of more of the aforementioned 
features was considered eligible to participate in the study.  At this point other information 
regarding demographics and diagnosis were gathered including patient contact information, cutis 
laxa onset, age of onset, and name and contact information of the physician who made the 
diagnosis. 
4.1.3 Informed Consent 
If the participant attended a research clinic at University of Pittsburgh Medical Center, 
information regarding the study and research activities was provided before arrival to the clinic, 
with informed consent occurring in person, but before any research activities were started.  If the 
subject was participating through his or her treating physician, the entire informed consent 
process had occurred over the phone, and the consent form had been signed before any research 
activities were performed.  
4.1.4 Research Activities 
Research activities varied based on whether the participant was coming to a research clinic in 
Pittsburgh or if he/she was participating through his/her local, treating physician.  It was possible 
for subjects to participate in both sets of activities. 
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4.1.4.1 Participation through Research Clinics for Affected Individuals  
For individuals participating through a Pittsburgh research clinic, activities after informed 
consent included: personal medical history, pedigree, CL questionnaire, blood and/or saliva 
sample, genetics physical exam and evaluation and skin biopsy, PFT and chest CT, respiratory 
questionnaires, echocardiogram, DEXA scan, skin elasticity testing, vascular elasticity testing, 
hearing testing, craniofacial imaging, and lymphedema measurements.  All of these tests were 
completed through the Montefiore Hospital Clinical and Translational Research Center (MUH 
CTRC). 
The genetics evaluation consisted of a targeted physical exam, which was completed by 
Dr. Madan-Khetarpal and Juliann McConnell, MS, CGC.  If permitted by the participant, clinical 
photographs were also obtained.  Also completed during the genetics evaluation was the CL 
questionnaire (see Appendix B), which details the personal medical history, pedigree, as well as 
phenotypic information by body system.  A skin biopsy was also performed on willing 
participants, which could be used for EM, histology, and growing fibroblasts.  Additionally, 
blood samples were collected for DNA, plasma, and serum.  If a blood sample could not be 
obtained, a saliva sample was collected for DNA isolation. 
Pulmonary function testing was performed both at Washington University in St. Louis 
and at University of Pittsburgh.  Testing was offered to any affected individual or known carrier 
of LTBP4 mutations over age 5 who attended a clinic.  Due to the lengthy test that required more 
complicated commands, it could not be completed on younger participants.  The pulmonary 
function test included spirometry, lung volumes, DLCO testing, and blood gas testing.  
Respiratory questionnaires were completed by the subjects or his/her adult parents.  The St. 
George’s Respiratory Questionnaire (SGRQ) was completed to assess how lung disease 
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impacted daily living, the Beck Depression Inventory (BDI) to assess level of depression, 
Shortness of Breath questionnaire to assess what level of activity leads to dyspnea, MRC 
questionnaire to assess how an individual’s lung disease affected activity level, the Stanford 
Brief Activity Survey determined level activity at work and in free time, and the Smoking 
History Form looked at the amount of direct and indirect smoke exposure over the lifetime.  
Echocardiograms were obtained at both University of Washington in St. Louis and at 
University of Pittsburgh.  These could be obtained on any individual around three years of age or 
older who was able to lie still for approximately 30 minutes.  Echocardiography was completed 
on any eligible affected individual or known LTBP4 carrier in attendance. 
DEXA scans, to assess bone density, were performed on all affected individuals and 
known LTBP4 carriers over the age of 18 who were not pregnant at the time of testing.  Women 
of childbearing potential were required to take a urine pregnancy test.  Reports generated 
included z-scores and t-scores on the spine and hip, with WHO classification of normal, 
osteopenia, or osteoporosis, as well as body fat composition analysis. 
Two types of elasticity testing were performed: skin elasticity and vascular elasticity.  
Skin elasticity testing was performed on all affected individuals and known LTBP4 carriers of 
any age.  We used an investigational device, DermaLab, which assesses skin elasticity and skin 
moisture, on a research basis.  Moisture testing began in 2012, while the skin elasticity testing 
began in 2011.  Vascular elasticity testing was performed at the University of Pittsburgh by the 
Vascular CTRC and is a non-invasive test that uses ultrasound to measure pulse wave velocity 
which depends on how elastic a person’s blood vessels are. 
Hearing testing was performed, when available, on any affected individual or known 
LTBP4 heterozygote over the age of 6.  The testing included otoscopy, tympanometry, 
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behavioral hearing, frequency-sweep distortion-product otoacoustic emissions (DPOAE), 
DPOAE input/output, and contralateral-supression DPOAE.  DPOAE testing looked at cochlear 
integrity, DPOAE input/output measured cochlear compression, and contralateral-supression 
DPOAE measured lower-brainstem integrity. 
Craniofacial imaging was performed using a 3-dimensional stereophotogrammetry 
system that consists of six cameras that generate a 3D image of the face.  This is performed on 
all affected individuals and known LTBP4 carriers who were able to sit still for at least five 
minutes. 
Lymphedema measurements were added in October 2011 and were performed in three 
different ways.  Numerous measurements were taken along the extremities.  Perometry was also 
performed, which used light beams and sensors to determine the extremity volume.  This was 
done to determine any asymmetry, which may be attributed to lymphedema.  Bioelectric 
impedance measured the electric properties of the extremities, with the goal of determining total 
water composition. 
4.1.4.2 Participation through Treating Physician for Affected Individuals  
For individuals participating through his/her treating physician, activities after informed 
consent included obtaining personal medical history, pedigree, blood or saliva sample, CL 
questionnaire, and a skin biopsy if the treating physician was able to collect one.  Additionally, 
medical record information, including echocardiograms, PFTs, chest CT, and other imaging 
performed to assess arterial tortuosity, diverticula, or hernias were collected and used in this 
analysis.   
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4.1.4.3 Participation for Unaffected First-Degree Relatives 
For unaffected first-degree relatives who were not known LTBP4 heterozygotes, 
participation involved informed consent, followed by a blood draw or saliva sample.  DNA was 
used to confirm genetic results in the proband or in whole exome sequencing and new gene 
discovery. 
4.1.5 Follow-up 
Follow-up consisted of yearly phone calls to note any changes in medical history, update the 
pedigree, and collect any new medical records of interest.  Additionally, some participants called 
more regularly for updated genetic testing information.  When a mutation was found, a 
participant was asked if he/she would like to know the results.  For those participants who 
wanted to know his/her mutation, results were shared over the phone and then a research 
mutation report was mailed to the participant or guardian. 
4.2 LABORATORY PROTOCOLS 
4.2.1 Mutation Analysis 
Mutation analysis was performed on DNA mostly from peripheral blood, or occasionally on 
saliva or fibroblasts cultured from a skin biopsy.  DNA was isolated using a phenol chloroform 
extraction of Qiagen’s PureGene System (Qiagen ©) for blood samples, and Genotek’s Oragene 
protocol (DNA Genotek) for saliva samples.  The concentration of the DNA preparation was 
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measured by UV spectrophotometry and working solutions were prepared at standard 50 ng/µl 
concentration. Exons and flanking intronic sequences of target genes (ELN, FBLN4, FBLN5, 
LTBP4, ATP6V0A2, PYCR1) were amplified by PCR. ExoSAP-IT and ABI BigDye Terminator 
Kit (Applied Biosystems) is used for PCR product cleaning and sequencing reaction.  
Sequencing of sense and antisense strands was done using the University of Pittsburgh Genomics 
and Proteomics core facility and analyzed using Sequencher (Gene Codes Corporation) and the 
UCSC Genomic Browser.  Confirmation of identified mutations was done on separate 
amplification products and sometimes through RNA studies. 
4.2.2 Electron Microscopy 
Skin biopsies obtained from the University of Pittsburgh research clinics or from a treating 
physician were fixed in glutaraldehyde, stained, and embedded in Epon embedding resin, 
sectioned, and examined with a Tecnai 12 transmission electron microscope (Urban et al 2009).   
4.3 PULMONARY ANALYSIS 
4.3.1 Respiratory Questionnaire Scoring 
The St. George’s Respiratory Questionnaire (SGRQ) (Jones et al 1991), Beck Depression 
Inventory (BDI) (Beck et al 1996), the MRC breathlessness scale (MRC) (Stenton 2008), and 
Stanford brief activity survey (Taylor-Piliae et al 2006) were scored according to the protocols 
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provided in the questionnaire manuals.  The Shortness of Breath questionnaire is scored by 
summing all responses for a total score.  
4.3.2 Statistical Analysis 
Statistical analysis was performed using SPSS version 19.  Two PFT datasets, congenital CL 
versus acquired CL and carriers of CL versus all CL, were analyzed.  Each dataset was first 
checked for normality, and then 2-tailed t-tests were run using α=0.05.  After this was 
performed, bivariate correlation was performed to determine the most correlated disability 
questionnaire scores to the most used PFT variables in COPD testing, both pre-bronchodilation 
(pre-BD) and post-bronchodilation (post-BD): FEV1 percent predicted, FVC percent predicted, 
and FEV1/FVC percent predicted.  The Odds Ratio was calculated using The MedCalc software 
(www.medcalc.org/calc/odds_ratio.php), the exact binomial test for goodness of fit was 
calculated using the University of Tennessee Health Center binomial program (http://biostat-
server.uthsc.edu/pt600/bintestframe.html), and the relative risks were calculated using The 
MedCalc software (http://www.medcalc.org/calc/relative_risk.php).  
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5.0  RESULTS 
The congenital subset consisted of 11 individuals, all of whom had congenital cutis laxa, with 
some individuals excluded from the post-BD analysis if bronchodilation was not indicated by the 
pre-bronchodilation results. No bronchodilation is performed if FEV1/FVC≥0.80 or if the subject 
was a minor, and therefore not permitted to receive bronchodilation per the study protocol.  One 
individual with CL who had a PFT was excluded from the congenital versus acquired CL as it 
was unclear what onset of CL she had. The acquired group consisted of 8 individuals, all of 
whom had acquired cutis laxa, with some of the individuals excluded from the post-BD analysis 
if bronchodilation was not indicated by the pre-bronchodilation results. The CL group consisted 
of 20 individuals, all of whom had cutis laxa, with some individuals excluded from the post-BD 
analysis if bronchodilation was not indicated by the pre-bronchodilation results or if the subject 
was a minor.  The individual with unknown CL onset was included in the CL group.  The 
unaffected carrier group consisted of 4 LTBP4 heterozygotes, who acted as controls.  Two of the 
carriers did not receive bronchodilation and were therefore excluded from the post-BD analysis. 
Demographic information, including CL affection status, age at PFT, sex, and gene status are 
summarized for all participants that were analyzed in Table 11 (Appendix B). 
 
 
 
29 
Table 3. Demographic Information by CL onset 
 
CL onset 
subgroup N 
Mean 
Age 
Age 
Range 
t-test 2-
tailed p-
value for 
age 
% 
Male 
% 
Female 
Exact 
binomial 
test for 
goodness 
of fit 
Congenital 11 25 3-58 45.45 54.55 P=0.500 
Acquired 8 55.75 39-68 
0.000 
 25 75 P=0.145 
Carrier 4 36.5 8-50 N/a 75 25 -- 
 
Data on age among the congenital and acquired subgroups was determined to have a 
normal distribution (see Table 18 in Appendix B).  As expected, the acquired group was older 
than the congenital group (Table 3), but was not older at a statistically significant level.  One 
possible reason for having more women in the acquired group is that acquired cutis laxa can be 
precipitated by autoimmune diseases, which are more common in women.  
 
Table 4. CL COPD and Asthma classification 
 
Pedigree 
ID 
Patient 
ID 
FEV1/FVC 
percent 
FEV1 
percent 
predicted 
COPD 
classification 
Previously 
diagnosed 
with asthma? 
Smoking 
pack 
years 
CL-004 7166 87 118 No COPD Yes 0 
CL-028 7034 52* 71* Moderate COPD* Yes 0 
CL-032 7040 49 34 Moderate COPD No 0 
CL-036 7044 50 41 Moderate COPD Yes 0.165 
CL-050 7065 84* 78* No COPD Don’t know 0 
CL-060 7078 36 39 Moderate COPD No 0 
CL-065 7093 55* 69* Moderate COPD* No 0.572 
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*Values or categorization based on pre-bronchodilation values 
 
COPD classification was determined for all individuals with post-bronchodilation PFT 
values, indicated in Table 4, with 50% of this CL population showing mild to moderate COPD 
(Table 5). Table 5 also shows a higher rate of asthma and COPD in this CL population compared 
to the general US population. The general US population data was obtained through the National 
Health Interview Survey, which contained 229,505 individuals in the 2010 survey, with 48.20% 
CL-068 7099 51 61 Moderate COPD Yes 0 
CL-094 7159 77 62 No COPD Don’t know 13.5 
CL-094 7160 61 87 Mild COPD Yes 0 
CL-095 7161 70 99 No COPD Yes 4 
CL-096 7162 63 73 Mild COPD No 0 
CL-109 7183 76* 104* No COPD No 12.5 
CL-114 7196 82* 85* No COPD No 0 
CL-115 7197 68 58 Moderate COPD Don’t know 0 
CL-116 7198 45 31 Moderate COPD Don’t know 0 
CL-117 7202 81* 77* No COPD Yes 0 
CL-120 7207 76* 78* No COPD No 0 
CL-121 7209 74 98 No COPD No 2.975 
CL-125 7226 82* 133* No COPD No 0 
Carriers 
CL-015 7006 81 89 No COPD Don’t know -- 
CL-015 7007 85 132 No COPD Don’t know 0 
CL-015 7192 86* 104* No COPD Yes 0 
CL-028 7035 84* 99* No COPD No 0 
Table 4 continued 
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of the individuals in the 18-44 year old range, 35.00% in the 45-64 year old range, and 16.8% in 
the 65 and older range (CDC 2012). 
Table 5. Pulmonary Statistics for CL versus General Population 
 
 Frequency 
of COPD 
Percent 
COPD 
Frequency 
of asthma 
Percent 
asthma 
Percent 
current 
smokers 
Cutis laxa 10 of 20 50 7 of 20 35 15 
(N=20) 
General 
population 
4,314 of 
229,505 
source: 
CDC 2012 
1.88 29,057 of 
229,505 
source: 
CDC 2012 
12.66 19.3  
source: 
CDC 
2010 
 
Table 6. Odds Ratio and Relative Risk for CL and the General Population 
 
 Odds Ratio Relative Risk 
COPD 52.20 (21.72-125.48), z: 8.839, 
p<0.0001 
27.10 (17.47-42.05),  
z: 14.723, p<0.0001 
Asthma 3.71 (1.48-9.31), z: 2.799, 
p=0.0051 
3.11 (1.71-5.66), z: 3.728, 
p=0.0002 
 
An odds ratio calculation (Table 6) with 95% CI was performed from the data in Table 5 
and determined that the cutis laxa cohort had a COPD odds ratio of 52.20 and a relative risk of 
27.10.  For asthma, the odds ratio was 3.71 and the relative risk was 3.11.  
Table 7. Age and Lung Function Differences in Asthma Diagnoses in CL 
 
 N Mean Std. Error Mean 2-tailed t-test 
p-value 
Age of individuals who were 
diagnosed with asthma 
9 22.02 5.23 
Age of individuals who were 
not diagnosed with asthma 
15 46.87 4.10 
.002 
Pre-BD FEV1 % predicted 5 74.40 15.08 
Post-BD FEV1 % predicted 5 81.20 13.65 
.025 
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There is a statistically significant difference in age of individuals who have been 
diagnosed with asthma and those who have not (Table 7).  For the individuals who have been 
diagnosed with asthma and have pre- and post-BD PFT information, the post-BD FEV1 % 
predicted goes to 81.20%.  As asthma is diagnosed as a fully reversible lung obstruction, none of 
the individuals in this group had full reversal of FEV1, indicating that none of these subjects 
actually have asthma. 
5.1.1 Lung Function Analysis of Congenital versus Acquired/Late-Onset CL 
Shapiro-Wilk analysis of PFT data in congenital and acquired CL (Table 19, Appendix B) was 
performed.  Given that all p-values in Table 19 were greater than 0.05, the null hypothesis was 
not rejected, meaning the data could be assumed to be normally distributed.  
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Table 8. Congenital versus Acquired CL Pre- and Post-BD 
 
 CL onset N Mean 
Std. 
Error 
Mean 
t-test 2-
tailed p-
value 
Mean % 
change pre- to 
post-BD 
Congenital  11 86.27 8.310 N/a FVC pre-BD  
percent predicted Acquired 8 78.50 7.447 .496 N/a 
Congenital 7 72.29 7.539 N/a FEV1/FVC pre-BD 
percent predicted Acquired 6 76.33 6.677 .695 N/a 
Congenital 11 67.73 9.465 N/a FEV1 pre-BD percent 
predicted Acquired 8 68.00 9.046 .984 N/a 
Congenital 6 82.33 11.83 N/a FVC pre-BD percent 
predicted Acquired 5 74.40 10.75 .631 N/a 
Congenital 5 65.00 8.47 N/a FEV1/FVC pre-BD 
percent predicted Acquired 5 71.60 5.77 .540 N/a 
Congenital 6 52.83 11.63 N/a FEV1 pre-BD  
percent predicted Acquired 5 55.40 10.25 .872 N/a 
Congenital 6 86.67 11.254 6.52 FVC post-BD  
percent predicted Acquired 5 82.00 9.236 .756 12.5 
Congenital 5 70.40 8.600 9.82 FEV1/FVC post-BD 
percent predicted Acquired 4 70.25 6.486 .989 3.45 
Congenital 6 60.33 11.152 17.13 FEV1 post-BD  
percent predicted Acquired 5 64.20 10.888 .810 3.45 
Congenital 9 72.89 9.932 N/a DLCO percent 
predicted Acquired 8 55.88 5.765 .163 N/a 
 
A 2-tailed t-test comparing congenital CL and Acquired CL with an α=0.05 had a p-value 
>0.05 for all variables tested, indicating there was not a statistically significant difference 
between congenital and acquired CL in any of the PFT variables tested (Table 8). P-values used 
did not assume equal variances.  Mean % change from pre- to post-BD (Table 8) shows that with 
bronchodilation, the population is not showing a full reversal of bronchodilation, which is 
indicative of COPD. 
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Figure 2. Plot of FEV1/FVC pre-BD percent predicted versus CL onset 
and gene status. 
 
Figure 2 is a visual representation of the lung function pre-bronchodilation for all CL 
subtypes.  Acquired CL, Congenital CL with no known mutation, and with ELN mutations 
appear to follow similar trends. 
5.1.2 Lung Function Analysis of CL versus Unaffected Carriers 
Shapiro-Wilk analysis of PFT data in unaffected carriers and individuals with cutis laxa (Table 
21, Appendix B) was performed.  Given that all p-values in Table 21 were greater than 0.05, the 
null hypothesis was not rejected, meaning the data could be assumed to be normally distributed.  
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Table 9. Affected CL versus Unaffected Carrier Pre-BD Group Statistics 
 
 
CL onset N Mean 
Std. Error 
Mean 
t-test 2-tailed 
p-value 
Carrier 4 99.2500 7.80358 FVC pre-BD  
percent predicted Cutis Laxa 20 84.6000 5.60892 .174 
Carrier 3 101.0000 3.46410 FEV1/FVC pre-
BD percent 
predicted  Cutis Laxa 14 76.0714 4.94304 .002 
Carrier 4 102.5000 9.66523 FEV1 pre-BD 
percent predicted Cutis Laxa 20 70.2500 6.61731 .032 
Carrier 3 88.0000 7.02377 DLCO percent 
predicted Cutis Laxa 18 65.6667 5.82366 .054 
 
 
A 2-tailed t-test comparing unaffected carriers and cutis laxa with a 95% CI has a p-value 
≤0.05 for FEV1 pre-BD and FEV1/FVC pre-BD, and a p-value >0.05 for FVC pre-BD, and 
DLCO variables (Table 9).  Statistical analysis was not done for post-BD values as only two 
carriers had post-BD data available. P-values used did not assume equal variances.   
5.1.3 Measures of Disability versus Lung Function Analysis 
Bivariate correlation was performed using disability assessing questionnaire scores in addition to 
all PFT variables included in previous analyses.  All disability raw data is in Table 16 (Appendix 
B), with results from the bivariate correlations included in Tables 22 and 23 (Appendix B).  This 
analysis indicated the SGRQ total score had the most significant correlations with the 
FEV1/FVC pre-BD PFT variable and the chest CT visual emphysema score.   
A linear regression comparing SGRQ total score to CT visual emphysema score, pre-BD 
FEV1/FVC, sex, and age indicated a p-value ≤0.05 for the CT visual emphysema score and pre-
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BD FEV1/FVC (Table 10).  Sex and age each had a p-value >0.05 when compared to the SGRQ 
total score (Table 10). 
 
Table 10. Disability and Pulmonary Function Correlation (n=5) 
 
 SGRQ 
total 
score 
CT visual 
emphysem
a score 
FEV1/FVC 
pre-BD 
percent 
predicted Sex 
Age at 
PFT 
SGRQ total score 1.000 .903 -.930 .118 .334 
CT visual 
emphysema score 
.903 1.000 -.853 -.089 -.092 
FEV1/FVC pre-BD 
percent predicted 
-.930 -.853 1.000 -.130 -.360 
Sex .118 -.089 -.130 1.000 .441 
Pearson 
Correlation 
Age at PFT .334 -.092 -.360 .441 1.000 
SGRQ total score . .018 .011 .425 .291 
CT visual 
emphysema score 
.018 . .033 .443 .441 
FEV1/FVC pre-BD 
percent predicted 
.011 .033 . .417 .276 
Sex .425 .443 .417 . .229 
Sig. (1-tailed)
Age at PFT .291 .441 .276 .229 . 
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6.0  DISCUSSION 
The purpose of this study was to better characterize the risk for COPD, validity of asthma 
diagnoses, pulmonary phenotype between congenital CL, acquired CL, and CL carrier, and 
disability from COPD.  The current literature does not provide information on lung disease 
outside of case series’ and review articles, making these findings novel to the CL community.  
Particularly lacking was a quantitative measurement of the risk of COPD in CL patients.  The 
most well known genetic risk factor for COPD is alpha-1 antitrypsin deficiency (Molfino 2007).  
Environmental risk factors include smoke exposure, either through tobacco smoke or second-
hand tobacco smoke exposure, occupational exposures, and air pollution (Eisner et al 2005 and 
Johannessen et al 2012).   
6.1.1 Increased Risk for COPD and Asthma Diagnoses 
The percentage of individuals with CL who had COPD by PFT and asthma by report, was 
notably higher than the general population rates of disease, with the COPD odds ratio showing 
those with CL had a 52.20 greater odds to have COPD than those of the general population. The 
relative risk (RR) for the CL population when compared to the general population was 27.10, 
indicating that individuals with CL were 27.10 times more likely as people in the general 
population to develop COPD. The risk for COPD in someone with an alpha-1-antitrypsin 
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deficiency was described by Dahl (2002) to have an odds ratio of 22 and relative risk of 12 for 
the ZZ genotype.  A study done by Johannessen et al (2012) showed that women who were 
exposed to environmental tobacco smoke (ETS) in childhood had an odds ratio of 1.9 at a 95% 
CI when compared to women who were not exposed to ETS.  Smokers also have an increased 
risk for developing COPD, with a study by Lundback et al (2003) showing that ex-smokers had 
an odds ratio of 2.14, people who smoked less than 5 cigarettes a day had an odds ratio of 4.39, 
people who smoked 5 to 14 cigarettes a day had an odds ratio of 6.44, and people who smoked 
more than 14 cigarettes a day had an odds ratio of 8.04, all with a 95% CI.  This is a lower odds 
ratio than determined for this CL cohort, demonstrating that CL has a higher risk for COPD then 
most of the well known COPD risk factors, which is something not previously reported in the 
literature.  
Additionally, 3 of 8 individuals who have COPD by PFT also reported having been 
diagnosed with asthma.  Since asthma is defined as being fully reversible with bronchodilation, 
the PFTs from these 3 individuals indicate that they have COPD, and do not have asthma.  The 
significantly different age in those who reported a previous asthma diagnosis and those that did 
not suggests that younger individuals with CL are more likely to be misdiagnosed as having 
asthma. Asthma diagnoses in the CL population should be follow-up with a more extensive 
examination.  Further investigations should assess the number of individuals being misdiagnosed 
with asthma when COPD is the correct diagnosis on a larger scale. 
6.1.2 Congenital versus Acquired CL Pulmonary Function 
Two-tailed t-test analysis indicated that there was no statistically significant difference between 
any PFT variables tested.  This suggests that the severity of COPD is not significantly different 
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between the two groups.  The separate analysis of the pre-BD variables in those who also had 
post-BD data also found no statistical difference between the congenital and acquired groups.  
This indicates that not only is there generally no difference found in lung dysfunction, but there 
is also no significant difference in those who specifically had an obstruction found on PFT. 
However, there was a statistically significant difference in the age between the congenital and 
acquired groups, with the congenital group being significantly younger. While additional 
participants should be tested to verify this finding with a larger sample size, the results are still 
important for cutis laxa management and our basic understanding of the connection between 
elastic fiber abnormalities and lung function. As lung function decreases with age, additionally 
analyses should include age-adjusted statistics. While there was no statistically significant 
difference in the sex distribution for either the congenital or acquired CL groups, the increase in 
females in the acquired group could be explained by the higher prevalence of autoimmune 
disease in women, which are a known trigger for acquired CL. 
Since congenital cutis laxa is characterized by an abnormality of elastic fiber formation, 
which is lung development in the context of COPD, and acquired cutis laxa is characterized by 
elastic fiber destruction, or lung fiber homeostasis in the context of COPD, lung dysfunction that 
is not significantly different in the congenital and acquired CL groups shows that elastic fiber 
formation and elastic fiber homeostasis are equally important.  This is the first study indicating 
that elastic fiber formation is equally important for lung development and lung homeostasis.   
The significance found in pre-BD PFT variables that was not seen in post-BD variables is 
not completely clear.  It is likely however, that the small number of subjects who were eligible 
for bronchodilation made our statistical analysis less powerful.  This will be important to re-
analyze after additional subjects are tested with bronchodilation. 
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6.1.3 Unaffected Carrier versus CL Pulmonary Function 
Two-tailed t-test analysis indicated that there was a statistically significant difference between 
unaffected carriers and subjects with CL for pre-BD FEV1 and pre-BD FEV1/FVC.  This shows 
that individuals with CL have significantly worse pulmonary function than carriers, which 
demonstrates that CL patients have an increased risk of COPD compared to carriers.  Additional 
PFTs on other subjects will help to better define this difference with a larger population. 
There were no statistically significant differences for any of the other PFT variables 
tested indicating that FEV1 and FEV1/FVC are the two most sensitive measures of lung 
function.  None of the LTBP4 carriers had COPD and in fact both the average FEV1 and 
FEV1/FVC values for this group were >100%, suggesting that heterozygous LTBP4 mutations 
do not have a detectable negative effect on lung function.  
6.1.4 Disability in CL 
The SGRQ, which looks at how much someone’s lung disease affects daily living, was found to 
be highly correlated with multiple lung function variables, specifically chest CT visual 
emphysema score and FEV1/FVC pre-BD.  This indicates that COPD has a significant impact on 
the morbidity and disability in the cutis laxa population and that it can be captured with the 
SGRQ.  This finding should be confirmed with additional subjects.  FEV1 was not significantly 
correlated with SGRQ total score. The Pearson correlation was -0.230 (Table 22), suggesting that 
the lack of statistical significance was from lack of correlation and not small sample size.  
Additional data collection may be helpful in determining whether the SGRQ could be used to 
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measure the impact of COPD severity on disability in cutis laxa and also if lung disease-related 
disability shows any differences based on genotype, CL onset, or other comorbidities.   
None of the other questionnaires were as highly correlated with lung function 
assessments as the SGRQ, suggesting that the SGRQ is the most sensitive disability 
questionnaire we currently have in the context of cutis laxa. However, the other questionnaires 
should be included in any analysis with additional subjects as with increased power other 
questionnaires may also show significance. 
6.1.5 Public Health Significance 
COPD is a major public health issue and one of the top causes of morbidity and mortality across 
the world.  Not only does COPD contribute to healthcare costs, but the associated quality of life 
issues, like disability, inability to work, and depression, increase the cost to the individual and to 
society.  Understanding how all of these factors are related is imperative to decreasing the burden 
of disease. 
6.1.6 Future Directions 
Future studies should include longitudinal data on existing subjects, additional subjects with lung 
function and disability data, and analyses on other complications of CL.  Longitudinal data on 
existing subjects would allow for the analysis of lung function and disability changes over time.  
Increasing the number of subjects with pulmonary function and disability data would not only 
increase the power of this analysis, but could lead to additional genotype-phenotype information 
that is not currently possible given the number of individuals included.  It would also be 
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important to understand the effect of other CL complications on disability.  While pulmonary 
function alone has a detectable effect, understanding disability in the full context of CL is also 
critical. 
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7.0  CONCLUSION 
We show significantly increased prevalence of COPD in cutis laxa patients compared to the 
general population and compared to LTBP4 mutation carriers. COPD in cutis laxa is a frequently 
debilitating complication, which is now understood to be similar in severity in both congenital 
and acquired cutis laxa. Additionally, the SGRQ total score is highly correlated with FEV1/FVC 
and CT visual emphysema score, indicating that the presence of COPD and the severity of 
emphysema significantly impact the morbidity and disability of CL patients.  This is significant, 
as no previously published studies have quantitatively assessed the differences in lung 
dysfunction or disability in the cutis laxa population.  Additional studies are required to further 
delineate the contribution of other manifestations of cutis laxa to the morbidity of affected 
individuals. 
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APPENDIX B: SUPPLEMENTARY DATA 
B.1 PARTICIPANT DEMOGRAPHICS FOR PFT ANALYSIS 
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Table 11. Participant Demographics for PFT Analysis 
 
Pedigree 
ID 
Patient 
ID 
CL Affection 
status 
Type of 
CL 
Age at 
PFT Sex Gene 
Mutation 
status 
CL-004 7166 Affected Unknown 34 F   
CL-028 7034 Affected Congenital 14 F LTBP4 Compound 
heterozygous 
CL-032 7040 Affected Congenital 58 F   
CL-036 7044 Affected Congenital 23 F LTBP4 Compound 
heterozygous 
CL-050 7065 Affected Acquired 66 F COL8A1 Heterozygous 
CL-060 7078 Affected Congenital 27 M   
CL-065 7093 Affected Congenital 23 F ATP6V0A2 Compound 
Heterozygous 
CL-068 7099 Affected Acquired 49 M   
CL-094 7159 Affected Congenital 43 F ELN Heterozygous 
CL-094 7160 Affected Congenital 16 M ELN Heterozygous 
CL-095 7161 Affected Congenital 40 M   
CL-096 7162 Affected Acquired 42 F   
CL-109 7183 Affected Acquired 68 F   
CL-114 7196 Affected Acquired 56 F   
CL-115 7197 Affected Acquired 64 F   
CL-116 7198 Affected Acquired 39 M   
CL-117 7202 Affected Congenital 11 M   
CL-120 7207 Affected Congenital 17 F   
CL-121 7209 Affected Acquired 62 F   
CL-125 7226 Affected Congenital 3 M ATP6V0A2 Compound 
heterozygous 
CL-015 7006 Carrier N/a 45 F LTBP4 Heterozygous  
CL-015 7007 Carrier N/a 43 M LTBP4 Heterozygous  
CL-015 7192 Carrier N/a 8 M LTBP4 Heterozygous  
CL-028 7035 Carrier N/a 50 M LTBP4 Heterozygous  
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B.2 PULMONARY FUNCTION RAW DATA 
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Table 12. FEV1 measurements from PFT testing 
 
Pedigree 
ID 
Patient 
ID Age 
Ref 
value 
(L) 
Pre-BD 
(L) 
Pre-BD 
% 
predicted 
Post-BD 
(L) 
Post-BD 
% 
predicted 
Post-BD 
% change 
CL-004 7166 34 2.35 2.73 116 2.78 118 2 
CL-028 7034 14 2.63 1.88 71    
CL-032 7040 58 2.51 0.78 31 0.86 34 9 
CL-036 7044 23 3.19 0.90 28 1.31 41 46 
CL-050 7065 66 2.33 1.82 78    
CL-060 7078 27 4.39 1.19 27 1.70 39 43 
CL-065 7093 23 3.38 2.32 69    
CL-068 7099 49 3.67 2.10 57 2.25 61 7 
CL-094 7159 43 2.67 1.59 60 1.66 62 5 
CL-094 7160 16 3.47 2.72 78 3.02 87 11 
CL-095 7161 40 3.80 3.52 93 3.78 99 7 
CL-096 7162 42 3.38 2.08 62 2.47 73 19 
CL-109 7183 68 2.38 2.48 104    
CL-114 7196 56 3.22 2.73 85    
CL-115 7197 64 2.35 1.03 44 1.36 58 32 
CL-116 7198 39 4.45 1.14 26 1.39 31 21 
CL-117 7202 11 2.81 2.17 77    
CL-120 7207 17 3.52 2.74 78    
CL-121 7209 62 22.48 2.19 88 2.43 98 13 
CL-125 7226 3 0.42 0.56 133    
CL-015 7006 45 3.24 2.73 80 2.89 89 6 
CL-015 7007 43 3.99 5.06 127 5.26 132 4 
CL-015 7192 8 1.80 1.88 104    
CL-028 7035 50 2.95 2.93 99    
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Table 13. FVC measurements from PFT testing 
 
Pedigree 
ID 
Patient 
ID Age 
Ref 
value 
(L) 
Pre-BD 
(L) 
Pre-BD 
% 
predicted 
Post-BD 
(L) 
Post-BD 
% 
predicted 
Post-BD % 
change 
CL-004 7166 34 2.74 3.14 115 3.21 117 2 
CL-028 7034 14 2.95 3.59 122    
CL-032 7040 58 3.24 1.67 52 1.76 54 5.10 
CL-036 7044 23 3.66 2.19 60 2.65 72 21 
CL-050 7065 66 3.05 2.16 71    
CL-060 7078 27 5.34 4.01 75 4.62 87 15 
CL-065 7093 23 3.91 4.22 108    
CL-068 7099 49 4.71 4.43 94 4.41 94 -0.50 
CL-094 7159 43 3.18 2.27 71 2.17 68 -4 
CL-094 7160 16 4.04 4.96 123 4.93 122 -1 
CL-095 7161 40 4.60 5.20 113 5.37 117 3 
CL-096 7162 42 4.19 3.39 81 3.92 94 16 
CL-109 7183 68 3.13 3.26 104    
CL-114 7196 56 4.13 3.34 81    
CL-115 7197 64 3.07 1.71 56 2.00 65 17 
CL-116 7198 39 5.60 2.40 43 3.06 55 27 
CL-117 7202 11 3.07 2.69 88    
CL-120 7207 17 3.98 3.59 90    
CL-121 7209 62 3.22 3.17 98 3.28 102 3 
CL-125 7226 3 1.45 0.68 47    
CL-015 7006 45 4.04 3.53 87 3.55 88 1 
CL-015 7007 43 5.05 6.14 122 6.21 123 1 
CL-015 7192 8 2.00 1.91  96    
CL-028 7035 50 3.75 3.48 92    
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Table 14. FEV1/FVC measurements from PFT testing 
 
Pedigree 
ID 
Patient 
ID Age 
Pre-BD 
% 
Pre-BD 
% 
predicted 
Post-
BD % 
Post-BD 
% 
predicted 
Post-BD 
% change 
CL-004 7166 34 87 101 87 101 0.00 
CL-028 7034 14 52     
CL-032 7040 58 47 59 49 61 4.10 
CL-036 7044 23 41  50   
CL-050 7065 66 84     
CL-060 7078 27 30 37 36 43 20.00 
CL-065 7093 23 55     
CL-068 7099 49 47 58 51 63 7.80 
CL-094 7159 43 70 83 77 91 9.00 
CL-094 7160 16 55 64 61 72 12.00 
CL-095 7161 40 68 82 70 85 4.00 
CL-096 7162 42 61 75 63 78 3.00 
CL-109 7183 68 76 100    
CL-114 7196 56 82     
CL-115 7197 64 60 78 68   
CL-116 7198 39 48 59 45 56 -4.00 
CL-117 7202 11 81 94    
CL-120 7207 17 76 87    
CL-121 7209 62 69 88 74 84 7.00 
CL-125 7226 3 82     
CL-015 7006 45 77 95 81 81 5.00 
CL-015 7007 43 82 101 85 105 4.00 
CL-015 7192 8 86     
CL-028 7035 50 84 107    
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Table 15. DLCO measurements from PFT testing and Chest CT results 
 
Pedigree 
ID 
Patient 
ID Age 
DLCO: 
Pre- or 
Post-BD 
DLCO ref 
value (mL CO/ 
min/mmHg) 
DLCO (mL 
CO/min 
/mmHg) 
DLCO % 
predicted 
Chest CT Visual 
emphysema score 
CL-004 7166 34 Pre-BD 26.88 21.12 79  
CL-028 7034 14 Pre-BD 20.60 13.00 63  
CL-032 7040 58 Post-BD 24.20 9.60 39 4 
CL-036 7044 23 Post-BD    1 
CL-050 7065 66 Pre-BD 23.20 10.90 47  
CL-060 7078 27 Post-BD 40.50 22.90 57 0 
CL-065 7093 23 Pre-BD 30.60 22.70 74 0 
CL-068 7099 49 Post-BD 34.50 21.00 61 4 
CL-094 7159 43 Pre-BD 37.51 22.03 59  
CL-094 7160 16 Pre-BD 21.70 29.94 138  
CL-095 7161 40 Pre-BD 31.83 30.22 96  
CL-096 7162 42 Post-BD 29.90 17.20 58  
CL-109 7183 68 Pre-BD 23.80 14.80 62 0 
CL-114 7196 56 Pre-BD 28.90 11.60 40 1 
CL-115 7197 64 Post-BD 23.40 12.40 53 0 
CL-116 7198 39 Post-BD 40.80 15.10 37 3 
CL-117 7202 11 Pre-BD 20.30 16.50 81  
CL-120 7207 17 Pre-BD 31.90 15.50 49  
CL-121 7209 62 Post-BD 24.20 21.40 89 2 
CL-125 7226 3 N/a 7.80    
CL-015 7006 45 Post-BD 3.49 25.80 74 1 
CL-015 7007 43 Post-BD 37.00 34.90 94 0 
CL-015 7192 8 Pre-BD     
CL-028 7035 50 Pre-BD 28.00 26.90 96 0 
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B.3 DISABILITY RAW DATA 
Table 16. Disability Questionnaire Scores 
 
Pedigree 
ID 
Patient 
ID 
SGRQ 
symptom 
score 
SGRQ 
activity 
score 
SGRQ 
impact 
score 
SGRQ 
total 
score 
Shortness 
of breath 
total 
BDI 
score 
Stanford 
brief activity 
score 
MRC 
total 
score 
CL-004 7166         
CL-028 7034 38.87 0.00 0.00 6.58 0 0 2  
CL-032 7040 66.30 85.80 36.00 56.10 59 3 1 4 
CL-036 7044 0.00 11.20 1.90 4.60 3 1 1 1 
CL-050 7065 53.00 93.30 58.40 68.90 50 18 1 3 
CL-060 7078         
CL-065 7093         
CL-068 7099 85.40 29.60 29.40 38.80 12 12 2 2 
CL-094 7159         
CL-094 7160         
CL-095 7161         
CL-096 7162 15.80 50.60 10.30 24.00     
CL-109 7183         
CL-114 7196 0.00 6.20 4.60 4.30 120 0 3 0 
CL-115 7197 38.18 23.72 1.90 15.15 6 6 3 2 
CL-116 7198         
CL-117 7202 40.38 0.00 0.00 5.85     
CL-120 7207 9.40 12.20 0.00 5.70 6 0 0 1 
CL-121 7209         
CL-125 7226 60.49 0.00 30.30 24.48 0 0 0 0 
CL-015 7006 18.40 0.00 0.00 2.65 0 2 1 0 
CL-015 7007 0.00 0.00 0.00 0.00 2 3 1 0 
CL-015 7192 21.69 0.00 8.34 7.47 0 0 1 0 
CL-028 7035 0.00 0.00 0.00 0.00 0 2 3 0 
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B.4 DISABILITY AND PFT CORRELATIONS 
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Table 17. PFT T-test analysis for Congenital versus Acquired CL  
 
 
Table 18. Congenital versus Acquired CL Age Normality Test 
 
 Shapiro-Wilk 
 CL onset Statistic df Two-tailed p-value 
Congenital .935 11 .459 
PFT age 
Acquired .900 8 .289 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
95% Confidence 
Interval of the 
Difference Equal 
Variances F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Diff 
Std. 
Error 
Diff Lower Upper 
Assumed 1.24 .28 .66 17 .514 7.77 11.65 -16.82 32.37 FVC pre-BD 
% predicted Not assumed   .69 16.92 .496 7.77 11.15 -15.77 31.32 
Assumed .45 .51 .31 9 .762 4.67 14.97 -29.21 38.54 FVC post-
BD % 
predicted 
Not assumed   .32 8.93 .756 4.67 14.55 -28.30 37.63 
Assumed .05 .81 -.02 17 .984 -.27 13.54 -28.84 28.29 FEV1 pre-
BD % 
predicted 
Not assumed   -.02 16.70 .984 -.27 13.09 -27.93 27.38 
Assumed .41 .53 -.24 9 .812 -3.87 15.76 -39.53 31.80 FEV1 post-
BD % 
predicted 
Not assumed 
  
-.24 8.93 .810 -3.87 15.58 -39.16 31.43 
Assumed .56 .46 -.39 11 .700 -4.05 10.23 -26.58 18.48 FEV1/FVC 
pre-BD % 
predicted 
Not assumed   -.40 10.99 .695 -4.05 10.07 -26.21 18.12 
Assumed .55 .47 .01 7 .990 .15 11.29 -26.55 26.85 FEV1/FVC 
post-BD % 
predicted 
Not assumed   .01 6.87 .989 .15 10.77 -25.41 25.71 
Assumed 1.74 .20 1.43 15 .173 17.01 11.87 -8.30 42.33 DLCO % 
predicted Not assumed   1.48 12.65 .163 17.01 11.48 -7.86 41.89 
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Table 19. Congenital versus Acquired CL Normality Test 
 
 Shapiro-Wilk 
 CL onset Statistic df P-value 
Congenital .914 5 .490 FVC pre-BD percent 
predicted Acquired .847 4 .216 
Congenital .918 5 .518 FVC post-BD percent 
predicted Acquired .776 4 .066 
Congenital .918 5 .520 FEV1 pre-BD percent 
predicted Acquired .972 4 .856 
Congenital .914 5 .494 FEV1 post-BD percent 
predicted Acquired .994 4 .976 
Congenital .910 5 .468 FEV1/FVC pre-BD  
percent predicted Acquired .883 4 .350 
Congenital .961 5 .812 FEV1/FVC post-BD 
percent predicted Acquired .936 4 .631 
Congenital .906 5 .441 DLCO percent predicted 
Acquired .959 4 .775 
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Table 20. PFT T-test analysis for CL versus CL Carrier 
 
 
 
 
 
 
 
 
Levene's Test 
for Equality 
of Variances t-test for Equality of Means 
95% Confidence 
Interval of the 
Difference 
 
 
Equal 
Variances F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Diff 
Std. 
Error 
Diff Lower Upper 
Assumed 1.939 .178 1.114 22 .277 14.65 13.15 -12.63 41.93 FVC pre-BD 
% predicted Not 
Assumed   
1.524 6.621 .174 14.65 9.61 -8.34 37.64 
Assumed .115 .741 .979 12 .347 18.25 18.63 -22.35 58.85 FVC post-BD 
% predicted Not 
Assumed   
.968 1.346 .475 18.25 18.86 -115.32 151.82 
Assumed 1.062 .314 2.072 22 .050 32.25 15.56 -.025 64.52 FEV1 pre-BD 
% predicted Not 
Assumed   
2.753 6.255 .032 32.25 11.71 3.87 60.63 
Assumed .036 .852 1.991 12 .070 43.75 21.97 -4.13 91.63 FEV1 post-
BD % 
predicted 
Not 
Assumed   
1.899 1.314 .260 43.75 23.03 -125.83 213.33 
Assumed 3.260 .091 2.257 15 .039 24.93 11.04 1.39 48.47 FEV1/FVC 
pre-BD % 
predicted 
Not 
Assumed   
4.130 11.25
7 
.002 24.93 6.04 11.68 38.18 
Assumed .127 .729 1.433 10 .182 19.60 13.68 -10.88 50.08 FEV1/FVC 
post-BD % 
predicted 
Not 
Assumed   
1.480 1.477 .317 19.60 13.25 -61.88 101.08 
Assumed .835 .372 1.511 19 .147 22.33 14.78 -8.60 53.27 DLCO % 
predicted Not 
Assumed   
2.448 5.395 .054 22.33 9.12 -.61 45.28 
58 
 
Table 21. Affected CL versus Unaffected Carrier Normality Test  
 
Shapiro-Wilk  
CL onset Statistic df P-value 
Carrier    
FVC pre-BD percent predicted 
Cutis Laxa .956 10 .744 
Carrier    
FVC post-BD percent predicted 
Cutis Laxa .909 10 .276 
Carrier    
FEV1 pre-BD percent predicted 
Cutis Laxa .939 10 .544 
Carrier    
FEV1 post-BD percent predicted 
Cutis Laxa .941 10 .565 
Carrier    
FEV1/FVC pre-BD percent predicted 
Cutis Laxa .966 10 .854 
Carrier    
FEV1/FVC post-BD percent predicted 
Cutis Laxa .983 10 .980 
Carrier    
DLCO percent predicted 
Cutis Laxa .897 10 .201 
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Table 22. Pearson Correlations for PFT Data Compared to Disability and PFT variables 
 
 CT visual 
emphysema 
score 
FVC 
pre-
BD 
% 
pred 
FVC 
post-
BD % 
pred 
FEV1 
pre-
BD 
% 
pred 
FEV1 
post-
BD % 
pred 
FEV1/FVC 
pre-BD % 
pred 
FEV1/FVC 
post-BD % 
pred 
DLCO 
% pred 
Pearson 
Correlation 
1 -.412 -.370 -.427 -.376 -.490 -.338 -.451 
Sig. (2-
tailed)  
.162 .327 .145 .319 .151 .459 .141 
CT visual 
emphysema 
score 
N 13 13 9 13 9 10 7 12 
Pearson 
Correlation 
-.412 1 .981** .508* .882** .468 .620* .723** 
Sig. (2-
tailed) 
.162 
 
.000 .011 .000 .058 .031 .000 
FVC pre-
BD percent 
predicted 
N 13 24 14 24 14 17 12 21 
Pearson 
Correlation 
-.370 .981** 1 .842** .862** .428 .555 .852** 
Sig. (2-
tailed) 
.327 .000 
 
.000 .000 .145 .061 .000 
FVC post-
BD percent 
predicted 
N 9 14 14 14 14 13 12 13 
Pearson 
Correlation 
-.427 .508* .842** 1 .992** .840** .901** .536* 
Sig. (2-
tailed) 
.145 .011 .000 
 
.000 .000 .000 .012 
FEV1 pre-
BD percent 
predicted 
N 13 24 14 24 14 17 12 21 
Pearson 
Correlation 
-.376 .882** .862** .992** 1 .825** .872** .708** 
Sig. (2-
tailed) 
.319 .000 .000 .000 
 
.001 .000 .007 
FEV1 post-
BD percent 
predicted 
N 9 14 14 14 14 13 12 13 
Pearson 
Correlation 
-.490 .468 .428 .840** .825** 1 .951** .323 
Sig. (2-
tailed) 
.151 .058 .145 .000 .001 
 
.000 .206 
FEV1/FVC 
pre-BD 
percent 
predicted 
N 10 17 13 17 13 17 12 17 
Pearson 
Correlation 
-.338 .620* .555 .901** .872** .951** 1 .437 
Sig. (2-
tailed) 
.459 .031 .061 .000 .000 .000  .155 
FEV1/FVC 
post-BD 
percent 
predicted 
N 7 12 12 12 12 12 12 12 
Pearson 
Correlation 
-.451 .723** .852** .536* .708** .323 .437 1 
Sig. (2-
tailed) 
.141 .000 .000 .012 .007 .206 .155  
DLCO 
percent 
predicted 
N 12 21 13 21 13 17 12 21 
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Table 22 Continued 
 
Pearson 
Correlation 
.846** -.308 -.373 -.201 -.480 -.848** -.879* -.373 
Sig. (2-
tailed) 
.008 .264 .410 .473 .276 .004 .049 .232 
SGRQ 
symptom 
score 
N 8 15 7 15 7 9 5 12 
Pearson 
Correlation 
.770* -.427 -.570 -.477 -.612 -.827** -.714 -.603* 
Sig. (2-
tailed) 
.025 .113 .182 .072 .144 .006 .176 .038 
SGRQ 
activity 
score 
N 8 15 7 15 7 9 5 12 
Pearson 
Correlation 
.962** -.445 -.368 -.068 -.528 -.881** -.864 -.491 
Sig. (2-
tailed) 
.000 .097 .416 .809 .223 .002 .059 .105 
SGRQ 
impact score
N 8 15 7 15 7 9 5 12 
Pearson 
Correlation 
.896** -.401 -.298 -.230 -.501 -.928** -.931 -.520 
Sig. (2-
tailed) 
.006 .155 .567 .429 .311 .001 .069 .101 
SGRQ total 
score 
N 7 14 6 14 6 8 4 11 
Pearson 
Correlation 
.255 -.235 -.580 -.174 -.537 -.703 -.645 -.644* 
Sig. (2-
tailed) 
.543 .440 .228 .570 .272 .078 .355 .044 
Shortness of 
breath 
N 8 13 6 13 6 7 4 10 
Pearson 
Correlation 
.514 -.116 .131 -.212 -.096 -.630 -.466 -.180 
Sig. (2-
tailed) 
.193 .705 .805 .488 .856 .129 .534 .618 
BDI total 
N 8 13 6 13 6 7 4 10 
Pearson 
Correlation 
-.310 .140 -.233 -.231 -.201 .051 -.473 .111 
Sig. (2-
tailed) 
.455 .647 .657 .448 .702 .914 .527 .760 
Stanford 
brief activity 
survey 
N 8 13 6 13 6 7 4 10 
Pearson 
Correlation 
.734* -.463 -.739 -.687* -.755 -.897** -.810 -.624 
Sig. (2-
tailed) 
.038 .130 .093 .014 .082 .006 .190 .073 
MRC total 
score 
N 8 12 6 12 6 7 4 9 
* Correlation is significant at the 0.01 level (2-tailed) 
**Correlation is significant at the 0.05 level (2-tailed) 
 
 
61 
Table 23. Pearson Correlations for Disability Scores Compared to Disability and PFT variables 
 
 
 
SGRQ 
symptom 
score 
SGRQ 
activity 
score 
SGRQ 
impact 
score 
SGRQ 
total 
score 
Shortness 
of breath 
BDI 
total 
Stanford 
brief 
activity 
survey 
MRC 
total 
score 
Pearson 
Correlation 
.846** .770* .962** .896** .255 .514 -.310 .734* 
Sig. (2-
tailed) 
.008 .025 .000 .006 .543 .193 .455 .038 
CT visual 
emphysema 
score 
N 8 8 8 7 8 8 8 8 
Pearson 
Correlation 
-.308 -.427 -.445 -.401 -.235 -.116 .140 -.463 
Sig. (2-
tailed) 
.264 .113 .097 .155 .440 .705 .647 .130 
FVC pre-BD 
percent 
predicted 
N 15 15 15 14 13 13 13 12 
Pearson 
Correlation 
-.373 -.570 -.368 -.298 -.580 .131 -.233 -.739 
Sig. (2-
tailed) 
.410 .182 .416 .567 .228 .805 .657 .093 
FVC post-
BD percent 
predicted 
N 7 7 7 6 6 6 6 6 
Pearson 
Correlation 
-.201 -.477 -.068 -.230 -.174 -.212 -.231 -.687* 
Sig. (2-
tailed) 
.473 .072 .809 .429 .570 .488 .448 .014 
FEV1 pre-
BD percent 
predicted 
N 15 15 15 14 13 13 13 12 
Pearson 
Correlation 
-.480 -.612 -.528 -.501 -.537 -.096 -.201 -.755 
Sig. (2-
tailed) 
.276 .144 .223 .311 .272 .856 .702 .082 
FEV1 post-
BD percent 
predicted 
N 7 7 7 6 6 6 6 6 
Pearson 
Correlation 
-.848** -.827** -.881** -.928** -.703 -.630 .051 -.897** 
Sig. (2-
tailed) 
.004 .006 .002 .001 .078 .129 .914 .006 
FEV1/FVC 
pre-BD 
percent 
predicted 
N 9 9 9 8 7 7 7 7 
Pearson 
Correlation 
-.879* -.714 -.864 -.931 -.645 -.466 -.473 -.810 
Sig. (2-
tailed) 
.049 .176 .059 .069 .355 .534 .527 .190 
FEV1/FVC 
post-BD 
percent 
predicted 
N 5 5 5 4 4 4 4 4 
Pearson 
Correlation 
-.373 -.603* -.491 -.520 -.644* -.180 .111 -.624 
Sig. (2-
tailed) 
.232 .038 .105 .101 .044 .618 .760 .073 
DLCO 
percent 
predicted 
N 12 12 12 11 10 10 10 9 
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Table 23 Continued 
 
Pearson 
Correlation 
1 .467 .702** .713** .008 .535 -.136 .648* 
Sig. (2-
tailed)  
.079 .004 .004 .980 .060 .657 .023 
SGRQ 
symptom 
score 
N 15 15 15 14 13 13 13 12 
Pearson 
Correlation 
.467 1 .791** .914** .422 .704** -.107 .933** 
Sig. (2-
tailed) 
.079 
 
.000 .000 .151 .007 .727 .000 
SGRQ 
activity 
score 
N 15 15 15 14 13 13 13 12 
Pearson 
Correlation 
.702** .791** 1 .952** .314 .725** -.278 .674* 
Sig. (2-
tailed) 
.004 .000 
 
.000 .296 .005 .357 .016 
SGRQ 
impact score 
N 15 15 15 14 13 13 13 12 
Pearson 
Correlation 
.713** .914** .952** 1 .306 .769** -.230 .841** 
Sig. (2-
tailed) 
.004 .000 .000 
 
.334 .003 .472 .001 
SGRQ total 
score 
N 14 14 14 14 12 12 12 11 
Pearson 
Correlation 
.008 .422 .314 .306 1 .141 .307 .270 
Sig. (2-
tailed) 
.980 .151 .296 .334  .646 .308 .396 
Shortness of 
breath 
N 13 13 13 12 13 13 13 12 
Pearson 
Correlation 
.535 .704** .725** .769** .141 1 .091 .611* 
Sig. (2-
tailed) 
.060 .007 .005 .003 .646 
 
.767 .035 
BDI total 
N 13 13 13 12 13 13 13 12 
Pearson 
Correlation 
-.136 -.107 -.278 -.230 .307 .091 1 -.025 
Sig. (2-
tailed) 
.657 .727 .357 .472 .308 .767  .938 
Stanford 
brief activity 
survey 
N 13 13 13 12 13 13 13 12 
Pearson 
Correlation 
.648* .933** .674* .841** .270 .611* -.025 1 
Sig. (2-
tailed) 
.023 .000 .016 .001 .396 .035 .938  
MRC total 
score 
N 12 12 12 11 12 12 12 12 
 * Correlation is significant at the 0.01 level (2-tailed) 
**Correlation is significant at the 0.05 level (2-tailed) 
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